Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Aims: To investigate the association of novel oral glucose‐lowering drugs ( GLDs ), compared with that of insulin, with risk of all‐cause mortality, cardiovascular disease ( CVD ) and severe hypoglycaemia. Methods: During 2013 to 2014 all patients with type 2 diabetes in Sweden identified as new users of novel oral GLDs , either dipeptidyl peptidase‐4 ( DPP ‐4) inhibitors or sodium‐glucose cotransporter‐2 ( SGLT2 ) inhibitors (only dapagliflozin available in Sweden during the study period), with those initiating insulin as a comparison group, in the Prescribed Drug Register were included and followed in the Patient and Cause of Death Registers. The novel GLD group and insulin group were matched 1:1 using propensity score. Cox regression models were used to estimate risks. Results: Of 37 603 patients, 21 758 were matched 1:1 to novel GLD vs insulin groups, with median follow‐up times of 1.51 years (16 304 patient‐years) and 1.53 years (16 306 patient‐years), respectively. Treatment with novel GLDs was associated with a 44% (hazard ratio [ HR ] 0.56 [95% confidence interval { CI } 0.49‐0.64]), 15% ( HR 0.85 [95% CI 0.73‐0.99]) and 74% (0.26 [95% CI 0.12‐0.57]) lower risk of all‐cause mortality, CVD and hypoglycaemia, respectively, compared with insulin treatment. In separate analyses for the two novel GLDs , dapagliflozin was associated with lower risks of all‐cause mortality and CVD (56% [ HR 0.44, 95% CI 0.28‐0.70] and 49% [ HR 0.51, 95% CI 0.30‐0.86], respectively), while DPP ‐4 inhibitor treatment was associated with lower risk of all‐cause mortality (41% [ HR 0.59, 95% CI 0.51‐0.67]), but not with CVD ( HR 0.87, 95% CI 0.75‐1.01). Conclusions: Novel oral GLD treatment was associated with lower risk of all‐cause mortality, CVD and severe hypoglycaemia compared with insulin treatment. Dapagliflozin was associated with a lower risk of both all‐cause mortality and CVD , whereas DPP ‐4 inhibitor treatment was only associated with lower risk of all‐cause mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“β-blockers 5306 (42) 11293 (45) 4596 (42) 4663 (43) .”
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
External review and validation of the Swedish national inpatient register
Ludvigsson, J. F., Andersson, E., Ekbom, A., Feychting, M., Kim, J.-L., Reuterwall, C., Heurgren, M., & Olausson, P. O. (2011) · BMC Public Health · doi:10.1186/1471-2458-11-450 · Cited by 5,055
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 2×
“Cancer 1897 (15) 6018 (24) 1780 (16) 1791 (16) .”
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015) · Diabetes Care · doi:10.2337/dc14-2441 · Cited by 3,066 · cited 4×
“Hemorrhagic 156 (1) 547 (2) 146 (1) 137 (1) .”
BackgroundInfluentialEffect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501352 · Cited by 2,577 · cited 2×
“Cancer 1897 (15) 6018 (24) 1780 (16) 1791 (16) .”
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · cited 1×
“Sulphonylurea 3763 (30) 7113 (28) 3405 (31) 3431 (32) .”
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Cited by
Kosiborod, M., Cavender, M. A., Fu, A. Z., Wilding, J. P., Khunti, K., Holl, R. W., Norhammar, A., Birkeland, K. I., Jørgensen, M. E., Thuresson, M., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.029190 · Cited by 813
Self-citationCardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
Kosiborod, M., Lam, C. S. P., Kohsaka, S., Kim, D. J., Karasik, A., Shaw, J., Tangri, N., Goh, S.-Y., Thuresson, M., Chen, H., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.009 · Cited by 461
Self-citationLytvyn, Y., Bjornstad, P., Udell, J. A., Lovshin, J. A., & Cherney, D. Z. I. (2017) · Circulation · doi:10.1161/circulationaha.117.030012 · Cited by 459
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Heerspink, H. J. L., Kosiborod, M., Inzucchi, S. E., & Cherney, D. Z. I. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.027 · Cited by 393
Birkeland, K. I., Jørgensen, M. E., Carstensen, B., Persson, F., Gulseth, H. L., Thuresson, M., Fenici, P., Nathanson, D., Nyström, T., Eriksson, J. W., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30258-9 · Cited by 362
Self-citation
Metadata
- Authors
- Nyström, T., Bodegard, J., Nathanson, D., Thuresson, M., Norhammar, A., & Eriksson, J. W.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-03-16
- Volume
- 19
- Issue
- 6
- Pages
- 831-841
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2585095576
- Cited by
- 84
- References
- 13
- FWCI
- 9.65
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. https://app.cochat.ai/papers/10.1111/dom.12889
- The paper
- Nyström, T., Bodegard, J., Nathanson, D., Thuresson, M., Norhammar, A., & Eriksson, J. W. (2017). Novel oral glucose‐lowering drugs are associated with lower risk of all‐cause mortality, cardiovascular events and severe hypoglycaemia compared with insulin in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12889
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.